APA

Lee S. E., Kim Y., Lee H., Yang H., Park C., Kim J., Kim S., Rhee M. & Oh B. (20120716). Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension. : Clinical therapeutics.

Chicago

Lee Sang Eun, Kim Yong-Jin, Lee Hae-Young, Yang Han-Mo, Park Chang-Gyu, Kim Jae-Joong, Kim Soon-Kil, Rhee Moo-Yong and Oh Byung-Hee. 20120716. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension. : Clinical therapeutics.

Harvard

Lee S. E., Kim Y., Lee H., Yang H., Park C., Kim J., Kim S., Rhee M. and Oh B. (20120716). Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension. : Clinical therapeutics.

MLA

Lee Sang Eun, Kim Yong-Jin, Lee Hae-Young, Yang Han-Mo, Park Chang-Gyu, Kim Jae-Joong, Kim Soon-Kil, Rhee Moo-Yong and Oh Byung-Hee. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension. : Clinical therapeutics. 20120716.